
CR4056
CAS No. 1004997-71-0
CR4056( CR 4056 | CR-4056 )
Catalog No. M10038 CAS No. 1004997-71-0
CR4056 (CR 4056, CR-4056) is a novel, orally active imidazoline-2 receptor (I2R) ligand with binding IC50 of 596 nM, also selectively inhibits the enzymatic activity of MAO-A with IC50 of 202.7 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 393 | Get Quote |
![]() ![]() |
10MG | 581 | Get Quote |
![]() ![]() |
25MG | 888 | Get Quote |
![]() ![]() |
50MG | 1242 | Get Quote |
![]() ![]() |
100MG | 1674 | Get Quote |
![]() ![]() |
500MG | 3348 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCR4056
-
NoteResearch use only, not for human use.
-
Brief DescriptionCR4056 (CR 4056, CR-4056) is a novel, orally active imidazoline-2 receptor (I2R) ligand with binding IC50 of 596 nM, also selectively inhibits the enzymatic activity of MAO-A with IC50 of 202.7 nM.
-
DescriptionCR4056 (CR 4056, CR-4056) is a novel, orally active imidazoline-2 receptor (I2R) ligand with binding IC50 of 596 nM, also selectively inhibits the enzymatic activity of MAO-A with IC50 of 202.7 nM; increases norepinephrine (NE) tissue levels both in the rat cerebral cortex and lumbar spinal cord, shows ED50 of 5.8 mg/kg in CFA rat model of inflammatory pain; shows high effectivity against bortezomib-induced painful neuropathy in rats.Pain Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsCR 4056 | CR-4056
-
PathwayGPCR/G Protein
-
TargetImidazoline Receptor
-
RecptorImidazoline Receptor
-
Research AreaNeurological Disease
-
IndicationPain
Chemical Information
-
CAS Number1004997-71-0
-
Formula Weight272.311
-
Molecular FormulaC17H12N4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1(C2=CC=CC=C2)=NC=C3C=C(N4C=CN=C4)C=CC3=N1
-
Chemical Name6-(1H-imidazol-1-yl)-2-phenylquinazoline
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ferrari F, et al. J Pain Res. 2011;4:111-25.
2. Thorn DA, et al. Br J Pharmacol. 2012 Jul;166(6):1936-45.
3. Meregalli C, et al. J Pain Res. 2012;5:151-67.
4. Lanza M, et al. Br J Pharmacol. 2014 Aug;171(15):3693-701.
molnova catalog



related products